Follow the news, literature, and elearning on new developments in the management of Heart Failure.
Based on the Heart Failure session and discussion during the 8th EPCCS Annual Meeting in Prague, this guidance document was written to help physicians diagnose and manage heart failure in their primary care practice.
Deferral of therapy with ACE inhibitors, beta-blockers, and aldosterone antagonists for 1 year carries an absolute mortality risk of around 1% per month, which is higher than the mortality risk due to therapy mentioned in patient information leaflets.
A meta-analysis showed that the rate of sudden death in HFrEF patients has fallen over the past two decades, suggesting a cumulative benefit of evidence-based medications on sudden death.
A brief version of our EPCCS Practical Guidance on Heart Failure Diagnosis and Management in Primary Care has now been published as Clinical Intelligence paper in the British Journal of General Practice.
In the BIOSTAT-CHF study, reaching less than 50% of the ESC guideline recommended dose of ACE-inhibitor/ARB or beta-blocker doses was associated with worse survival in HF patients.
Good adherence to treatment guidelines, in particular prescription of appropriate classes and doses of medications for heart failure, is associated with improved clinical outcomes.
Expert members of AF-SCREEN propose systematic or opportunistic screening approaches for AF based on known published data, to reduce the number of strokes and death.
ESC HF 2017 Based on heart sounds, respiration rate, and volume, thoracic impedance, night heart rate, and daily activity HeartLogic predicts the risk of an HF event independent of baseline variables.
ESC HF 2017 Pooled individual patient data reveal that slowing heart rate with a betablocker lowers mortality in sinus rhythm, while in AF patients baseline or attained heart rate does not affect mortality.
ESC HF 2017 Analysis of CHARM data revealed that outcomes improve with increasing EF up to ~50%, and that candesartan is effective in HFrEF and HFmrEF, but not in HFpEF.
ESC HF 2017 In EDIFY, treatment with ivabradine for 8 months reduced heart rate, but did not improve E/e’, exercise capacity or NT-proBNP levels in patients with HFpEF.
In the SPRINT trial, targeting an SBP of <120 mmHg, as compared with <140 mmHg, significantly reduced the risk of developing ADHF by 36% in all predetermined subgroups.